Research and Development

Lionel Goldfrank has been elected to sit on the board of the US-based biotech firm Egenix. Goldfrank is to succeed Donald …

The FT Global Pharmaceutical and Biotechnology Conference held in London recently asked: “What will the life science company of the …

Dr Andrew Plump will be joining Takeda in February from Sanofi to lead its global R&D operations as chief medical …

Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …

The government has committed to a £6 billion investment in scientific research and development as part of its science and …

Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …

Roche intends to grow at its March annual general meeting via the election of Bernard Poussot and Richard Lift who …

The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to …

Drug regulators should switch to adaptive pathways as the preferred approach to bringing future new medicines to patients, according to …

A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …

UK firm The Cell Therapy Catapult has chosen to build a £55 million state-of-the-art cell therapy manufacturing centre in Stevenage. …

Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …

Dr Philippe Bishop is joining the California-based biopharma firm Gilead from Genentech to be the company’s senior vice president of …

Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …

Riemser Pharma in Germany has appointed Dr Thomas Werner to its advisory board. The former head of GlaxoSmithKline and Bristol-Myers …